Bayer says 2024 sales of prostate cancer drug above $1 billion

Bayer on Thursday predicted at least $1 billion in 2024 sales for prostate cancer drug Nubeqa, which is playing a bigger role for the drugmaker's growth prospects after the failure of a promising anti-blood-clotting therapy. "Nubeqa … is set for continued growth in prostate cancer and is on track to reach blockbuster status this year – only five years after first indication launch," it said in a statement. Blockbuster is an industry term for drugs with at least $1 billion in annual sales.